In November 2023, to stimulate research for infant genetic disease, Fabric Genomics teamed up with DNAnexus and Oxford Nanopore Technologies to develop CLIA/CAP-certified laboratories in neonatal intensive care units and pediatric intensive care units. By utilizing the new genomic sequencing platform by Oxford Nanopore, the team will enable genetic screening on newborns to identify rare infant genetic diseases quickly and accurately. The ultimate long-term objective of this program is to provide gene information promptly to enhance treatment and patient outcomes in critical care settings. The collaboration will improve early diagnosis and treatment of genetic disease in infants through optimizing genetic testing procedures and building additional diagnostic capacity for pediatric and neonatal intensive care unit clinicians using the combination of Fabric Genomics' cloud-based artificial intelligence platform and DNAnexus' cloud-based data platform.
In February 2023, Illumina, Inc. partnered with the African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) to create a training institute to build genomic capacity in Africa. The collaboration seeks to train African scientists, clinicians, and researchers in genomic technology to respond to the growing need for advanced genetic research into infectious diseases. By providing the local talent with the appropriate skills and capacity, the project aims to increase genetic monitoring, accelerate disease research, and enhance the protection of the public against infectious diseases. This partnership is a reflection of Illumina's devotion to global health innovation constructing and developing genomics infrastructure construction in Africa as a means of fighting health-related challenges.
In January 2023, to encourage enhanced analysis and testing capability for cancer research as well as clinical use, SOPHiA GENETICS partnered with the Memorial Sloan Kettering Cancer Center (MSK). Leveraging the data analytics platform of SOPHiA GENETICS driven by artificial intelligence, the partnership is hoping to deliver groundbreaking genomic solutions to MSK clinicians and researchers. The collaboration aims to develop the ability to analyze challenging genomic data to bring more accurate diagnosis and personalized treatment to cancer patients. The collaboration is aimed at driving oncology outcomes, supporting efficient clinical decision-making, and enabling new, precision-mediated cancer therapies for cancer patients through the combination of MSK's exceptional cancer research and SOPHiA's data-centric know-how in genetic analysis.
In April 2022, to enable the application of data science in biotech companies, QIAGEN rolled out its Biomedical Knowledge Base throughout Europe, Japan, North America, and Australia. To enable high-speed-powered R&D within the field of biotechnology, the new platform integrates vast biological data, such as transcriptomic, proteomic, and genomic data. By the provisioning of advanced data interpretation and analysis skills to researchers, the Biomedical Knowledge Base facilitates more successful drug development, biomarker identification, and individualized medicine methodologies. QIAGEN offers an end-to-end cloud-based data-driven knowledge repository that empowers biotech companies to make worthwhile decisions and propel scientific breakthroughs, driving innovation in turn in the health care and life sciences community.
The genomics industry is registering exponential growth all over the world with the speed at which innovations take place for sequencing equipment and increased spending on research.
Increased public and private genomics research investment also drives market growth because it encourages personalized care and precision medicine. The increasing incidence of cancer and genetic diseases is also a major driver, as earlier treatment and detection are significantly enabled by genomic technology.
The convergence of artificial intelligence and machine learning with genomic data is accelerating data analysis, speeding up the detection of new biomarkers, and enhancing patient care. The growing need for personalized medicine, as well as the expanding application of genomics in pharmaceutical development, is also contributing to the market expansion at a fast pace.
Sources:
Company: SOPHiA GENETICS, Illumina, Inc., Oxford Nanopore Technologies
